Clinical Research Papers:
CT-guided 125I brachytherapy for recurrent ovarian cancer
Metrics: PDF 947 views | HTML 1606 views | ?
Ping Liu1, Lina Tong1, Bin Huo2, Dong Dai3, Wenxin Liu4, Ke Wang4, Ying Wang1, Zhi Guo1 and Hong Ni1
1 Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China
2 Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin, People’s Republic of China
3 Department of Molecule Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
4 Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
Hong Ni, email:
Zhi Guo, email:
Keywords: 125I seeds, brachytherapy, recurrent ovarian cancer
Received: February 17, 2016 Accepted: February 20, 2017 Published: March 04, 2017
This retrospective study was to evaluate the local control and survival of 125I brachytherapy for recurrent ovarian cancer. 52 125I brachytherapy procedures were performed in 47 patients with 51 recurrent ovarian cancer lesions. The follow-up period was 1-55 months (median 12 months). The local control rate (LC) of 3, 6, 12, 24 and 36 months was 93.3%, 77.7%, 58.9%, 38.7% and 19.3%, respectively. Patients with tumor size ≤ 4cm (85.7% vs 40.0%, P = 0.037) and actual D90 between 110 to 130Gy (47.4% vs 66.7% vs 62.5%, P = 0.029) had better LC. The 1, 2 and 3 years of overall survival (OS) was 79.3%, 63.0% and 52.5%, respectively. The poor performance status (HR 3.821, 95% CI 1.383-10.555; P = 0.010), concurrent distant metastasis (HR 9.222, 95% CI 1.710-49.737; P = 0.010) and large postoperative residual tumor size (HR 6.157, 95% CI 1.438-26.367; P = 0.014) were closely correlated with a poor OS. Our data indicate thatCT-guided 125I brachytherapy is an effective and safe modality for the local treatment of recurrent ovarian cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.